Recently Added Drugs
1. Attruby patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12539290 | BRIDGEBIO | NA |
Aug, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2029 |
| Orphan Drug Exclusivity(ODE-506) | Nov 22, 2031 |
Drugs and Companies using ACORAMIDIS HYDROCHLORIDE ingredient
NCE-1 date: 22 November, 2028
Market Authorisation Date: 22 November, 2024
Treatment: NA
Dosage: TABLET
More Information on Dosage
ATTRUBY family patents
2. Blujepa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12528809 | GLAXOSMITHKLINE | Crystalline Forms Of Gepotidacin |
Dec, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-978) | Dec 11, 2028 |
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Mar 25, 2035 |
Drugs and Companies using GEPOTIDACIN MESYLATE ingredient
NCE-1 date: 25 March, 2029
Market Authorisation Date: 25 March, 2025
Treatment: Treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kg with uncomplicated urinary tract infections (uuti) caused by e. coli, k. pneumoniae, citrobacter freu...
Dosage: TABLET
More Information on Dosage
BLUJEPA family patents
3. Brekiya (autoinjector) patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12533351 | AMNEAL | NA |
Feb, 2039
(12 years from now) | |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Market Authorisation Date: 14 May, 2025
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
BREKIYA (AUTOINJECTOR) family patents
4. Bylvay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12545705 | IPSEN | Ibat Inhibitors For The Treatment Of Liver Diseases |
Nov, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-918) | Jun 13, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2026 |
| Orphan Drug Exclusivity(ODE-363) | Jul 20, 2028 |
| Orphan Drug Exclusivity(ODE-436) | Jun 13, 2030 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: 20 July, 2025
Market Authorisation Date: 20 July, 2021
Treatment: Method of treating cholestatic pruritus in patients 12 months or older suffering from alagille syndrome (algs)
Dosage: CAPSULE, PELLETS; CAPSULE
More Information on Dosage
BYLVAY family patents
5. Cyklx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11096922 | AM GENOMICS | Anesthetic Composition And Method Of Anesthetizing The Eye |
Mar, 2039
(12 years from now) | |
| US11826347 | AM GENOMICS | Anesthetic Composition And Method Of Anesthetizing The Eye |
Mar, 2039
(12 years from now) | |
| US12403126 | AM GENOMICS | Anesthetic Composition And Method Of Anesthetizing The Eye |
Mar, 2039
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 15, 2028 |
Drugs and Companies using ARTICAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 August, 2025
Treatment: Method of anesthetizing an ocular surface via topical administration prior to ocular procedures and/or intraocular injections; Method of anesthetizing an ocular surface prior to ocular procedures and/...
Dosage: SOLUTION/DROPS
More Information on Dosage
CYKLX family patents
6. Daybue patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9212204 (Pediatric) | ACADIA | Treatment Of Rett Syndrome Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid |
Jul, 2032
(6 years from now) | |
|
US11370755 (Pediatric) | ACADIA | Compositions Of Trofinetide |
Feb, 2041
(14 years from now) | |
|
US11827600 (Pediatric) | ACADIA | Crystalline Forms Of Trofinetide |
Jan, 2043
(16 years from now) | |
|
US12492167 (Pediatric) | ACADIA | Crystalline Forms Of Trofinetide |
Jan, 2043
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2028 |
| Pediatric Exclusivity(PED) | Sep 10, 2028 |
| Orphan Drug Exclusivity(ODE-425) | Mar 10, 2030 |
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 11 March, 2027
Market Authorisation Date: 10 March, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
DAYBUE family patents
7. Daybue Stix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9212204 (Pediatric) | ACADIA | Treatment Of Rett Syndrome Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid |
Jul, 2032
(6 years from now) | |
|
US11370755 (Pediatric) | ACADIA | Compositions Of Trofinetide |
Feb, 2041
(14 years from now) | |
|
US11827600 (Pediatric) | ACADIA | Crystalline Forms Of Trofinetide |
Jan, 2043
(16 years from now) | |
|
US12492167 (Pediatric) | ACADIA | Crystalline Forms Of Trofinetide |
Jan, 2043
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2028 |
| Pediatric Exclusivity(PED) | Sep 10, 2030 |
| ODE*(ODE*) | Mar 10, 2030 |
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 11 March, 2027
Market Authorisation Date: 11 December, 2025
Treatment: NA
Dosage: FOR SOLUTION
More Information on Dosage
DAYBUE STIX family patents
8. Defitelio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12529052 | JAZZ | NA |
Jun, 2032
(6 years from now) | |
| US12534722 | JAZZ | NA |
Jun, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2021 |
| Orphan Drug Exclusivity(ODE) | Mar 30, 2023 |
| Orphan Drug Exclusivity(ODE-112) | Mar 30, 2023 |
Drugs and Companies using DEFIBROTIDE SODIUM ingredient
NCE-1 date: 30 March, 2020
Market Authorisation Date: 30 March, 2016
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of DEFITELIO before its drug patent expiration?
More Information on Dosage
DEFITELIO family patents
9. Dojolvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12551461 | ULTRAGENYX | NA |
Nov, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 30, 2025 |
| Orphan Drug Exclusivity(ODE-311) | Jun 30, 2027 |
Drugs and Companies using TRIHEPTANOIN ingredient
NCE-1 date: 30 June, 2024
Market Authorisation Date: 30 June, 2020
Treatment: NA
Dosage: LIQUID
How can I launch a generic of DOJOLVI before its drug patent expiration?
More Information on Dosage
DOJOLVI family patents
10. Elucirem patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12064487 | GUERBET | Complex Of Gadolinium And A Chelating Ligand Derived From A Diastereoisomerically Enriched Pcta And Preparation And Purification Process |
Jan, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2027 |
Drugs and Companies using GADOPICLENOL ingredient
NCE-1 date: 21 September, 2026
Market Authorisation Date: 21 September, 2022
Treatment: Method of magnetic resonance imaging to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax,...
Dosage: SOLUTION
More Information on Dosage
ELUCIREM family patents
11. Firmagon patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12533387 | FERRING | NA |
Feb, 2029
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 24, 2013 |
Drugs and Companies using DEGARELIX ACETATE ingredient
NCE-1 date: 24 December, 2012
Market Authorisation Date: 24 December, 2008
Treatment: Treatment of advanced prostate cancer
Dosage: POWDER
How can I launch a generic of FIRMAGON before its drug patent expiration?
More Information on Dosage
FIRMAGON family patents
12. Gavreto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12448366 | RIGEL | Solid Forms Of Pralsetinib |
Jul, 2042
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12539303 | RIGEL | NA |
Apr, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2025 |
| Orphan Drug Exclusivity(ODE-318) | Sep 04, 2027 |
| Orphan Drug Exclusivity(ODE-340) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-341) | Dec 01, 2027 |
Drugs and Companies using PRALSETINIB ingredient
NCE-1 date: 04 September, 2024
Market Authorisation Date: 04 September, 2020
Treatment: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractor...
Dosage: CAPSULE
More Information on Dosage
GAVRETO family patents
13. Impoyz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11179465 | PRIMUS | Topical Compositions Comprising A Corticosteroid |
Aug, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 28, 2020 |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: Treatment of plaque psoriasis
Dosage: CREAM
How can I launch a generic of IMPOYZ before its drug patent expiration?
More Information on Dosage
IMPOYZ family patents
14. Inlyta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12534530 | PF PRISM CV | NA |
Feb, 2035
(8 years from now) | |
|
US12534530 (Pediatric) | PF PRISM CV | NA |
Aug, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2017 |
Drugs and Companies using AXITINIB ingredient
NCE-1 date: 28 January, 2016
Market Authorisation Date: 27 January, 2012
Treatment: A first-line method of treating advanced renal cell carcinoma in an individual by administering axitinib at a starting dose of 5 mg twice daily in combination with pembrolizumab, where the axitinib do...
Dosage: TABLET
How can I launch a generic of INLYTA before its drug patent expiration?
More Information on Dosage
INLYTA family patents
15. Jardiance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US12527810 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | Jun 26, 2018 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Indication(I-869) | Aug 18, 2024 |
| M(M-82) | Feb 24, 2025 |
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-922) | Sep 21, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 01 August, 2014
Treatment: NA
Dosage: TABLET
How can I launch a generic of JARDIANCE before its drug patent expiration?
More Information on Dosage
JARDIANCE family patents
16. Livtencity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12527771 | TAKEDA | NA |
Oct, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2026 |
| Orphan Drug Exclusivity(ODE-388) | Nov 23, 2028 |
Drugs and Companies using MARIBAVIR ingredient
NCE-1 date: 23 November, 2025
Market Authorisation Date: 23 November, 2021
Treatment: NA
Dosage: TABLET
How can I launch a generic of LIVTENCITY before its drug patent expiration?
More Information on Dosage
LIVTENCITY family patents
17. Mayzent patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12533340 | NOVARTIS | NA |
Apr, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 26, 2024 |
| M(M-274) | Mar 01, 2025 |
Drugs and Companies using SIPONIMOD ingredient
NCE-1 date: 27 March, 2023
Market Authorisation Date: 26 March, 2019
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults receiving a beta-bloc...
Dosage: TABLET
How can I launch a generic of MAYZENT before its drug patent expiration?
More Information on Dosage
MAYZENT family patents
18. Mounjaro patent expiration
MOUNJARO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12343382 | ELI LILLY | Methods Of Using A Gip/Glp1 Co-Agonist For Therapy |
Jul, 2039
(13 years from now) | |
| US12295987 | ELI LILLY | Method of using a GIP/GLP1 co-agonist for diabetes |
Dec, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
| New Patient Population(NPP) | Dec 19, 2028 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: Treatment of type 2 diabetes by administering a once weekly escalation dose of 2.5 mg, 7.5 mg, or 12.5 mg of tirzepatide for at least 2 weeks and a once-weekly maintenance dose of 5 mg, 10 mg, or 15 m...
Dosage: SOLUTION
More Information on Dosage
MOUNJARO family patents
19. Mounjaro Kwikpen patent expiration
MOUNJARO KWIKPEN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12343382 | ELI LILLY | Methods Of Using A Gip/Glp1 Co-Agonist For Therapy |
Jul, 2039
(13 years from now) | |
| US12295987 | ELI LILLY | Method of using a GIP/GLP1 co-agonist for diabetes |
Dec, 2041
(15 years from now) | |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: Method of improving glycemic control by administering a first once-weekly dose of 2.5 mg tirzepatide for 4 weeks, increasing the once-weekly dose by increments of 2.5 mg to a once-weekly maintenance d...
Dosage: SOLUTION
More Information on Dosage
MOUNJARO KWIKPEN family patents
20. Myfembree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12551447 | SUMITOMO AM | NA |
Nov, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 26, 2024 |
| New Indication(I-898) | Aug 05, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
| M(M-289) | Jan 27, 2026 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 26 May, 2021
Treatment: NA
Dosage: TABLET
How can I launch a generic of MYFEMBREE before its drug patent expiration?
More Information on Dosage
MYFEMBREE family patents
21. Opzelura patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12544381 | INCYTE | NA |
May, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 21, 2024 |
| New Indication(I-896) | Jul 18, 2025 |
| Pediatric Exclusivity(PED) | Jan 18, 2026 |
| New Patient Population(NPP) | Sep 18, 2028 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 21 September, 2021
Treatment: NA
Dosage: CREAM
How can I launch a generic of OPZELURA before its drug patent expiration?
More Information on Dosage
OPZELURA family patents
22. Orladeyo patent expiration
Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12545645 | BIOCRYST | NA |
Nov, 2039
(13 years from now) | |
| US12545646 | BIOCRYST | NA |
Nov, 2039
(13 years from now) | |
| US12545647 | BIOCRYST | NA |
Nov, 2039
(13 years from now) | |
| US12552750 | BIOCRYST | NA |
Nov, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 03, 2025 |
| Orphan Drug Exclusivity(ODE-333) | Dec 03, 2027 |
| Pediatric Exclusivity(PED) | Jun 11, 2029 |
| New Product(NP) | Dec 11, 2028 |
Drugs and Companies using BEROTRALSTAT DIHYDROCHLORIDE ingredient
NCE-1 date: 03 December, 2024
Market Authorisation Date: 03 December, 2020
Treatment: NA
Dosage: CAPSULE; PELLETS
How can I launch a generic of ORLADEYO before its drug patent expiration?
More Information on Dosage
ORLADEYO family patents
23. Orlynvah patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12544337 | ITERUM | NA |
Dec, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 25, 2029 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 25, 2034 |
Drugs and Companies using PROBENECID; SULOPENEM ETZADROXIL ingredient
NCE-1 date: 25 October, 2028
Market Authorisation Date: 25 October, 2024
Treatment: Use in treating uncomplicated urinary tract infections caused by escherichia coli, klebsiella pneumoniae, or proteus mirabilis
Dosage: TABLET
More Information on Dosage
ORLYNVAH family patents
24. Phyrago patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12544376 | HANDA | NA |
Jan, 2041
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-307) | Dec 05, 2026 |
Drugs and Companies using DASATINIB ingredient
Market Authorisation Date: 05 December, 2023
Treatment: Use of dasatinib for treatment of newly diagnosed adults with ph+ cml in chronic phase, when coadministered with a gastric acid reducing agent
Dosage: TABLET
More Information on Dosage
PHYRAGO family patents
25. Pliaglis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12558328 | CRESCITA | NA |
Jan, 2031
(4 years from now) | |
Drugs and Companies using LIDOCAINE; TETRACAINE ingredient
Market Authorisation Date: 29 June, 2006
Treatment: A method of applying a solid forming local anesthetic formulation to a skin surface, allowing the layer to form a cohesive film, and removing the film layer by peeling from the skin surface as one, tw...
Dosage: CREAM
More Information on Dosage
PLIAGLIS family patents
26. Romvimza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12551483 | DECIPHERA | NA |
Dec, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2030 |
Drugs and Companies using VIMSELTINIB ingredient
NCE-1 date: 14 February, 2029
Market Authorisation Date: 14 February, 2025
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
ROMVIMZA family patents
27. Symbravo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12551488 | AXSOME | NA |
May, 2040
(14 years from now) | |
| US12551489 | AXSOME | NA |
May, 2040
(14 years from now) | |
| US12544383 | AXSOME | NA |
Mar, 2045
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2028 |
Drugs and Companies using MELOXICAM; RIZATRIPTAN BENZOATE ingredient
Market Authorisation Date: 30 January, 2025
Treatment: Acute treatment of migraine
Dosage: TABLET
How can I launch a generic of SYMBRAVO before its drug patent expiration?
More Information on Dosage
SYMBRAVO family patents
28. Synjardy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12527810 | BOEHRINGER INGELHEIM | NA |
Apr, 2033
(7 years from now) | |
|
US12527810 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Patient Population(NPP) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 26 August, 2015
Treatment: Use of empagliflozin as an adjunct to diet and exercise to improve glycemic control in pediatric patients aged 10 years to 17 years with type 2 diabetes mellitus
Dosage: TABLET
How can I launch a generic of SYNJARDY before its drug patent expiration?
More Information on Dosage
SYNJARDY family patents
29. Tepadina And Sodium Chloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9931458 | ADIENNE | Multi chamber flexible bag and methods of using same |
May, 2037
(11 years from now) | |
Drugs and Companies using THIOTEPA ingredient
Market Authorisation Date: 26 January, 2017
Treatment: NA
Dosage: POWDER
More Information on Dosage
TEPADINA AND SODIUM CHLORIDE family patents
30. Vizz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12533347 | LENZ | NA |
Oct, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2030 |
Drugs and Companies using ACECLIDINE HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2029
Market Authorisation Date: 31 July, 2025
Treatment: Treatment of presbyopia
Dosage: SOLUTION/DROPS
More Information on Dosage
VIZZ family patents
31. Vraylar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7943621 (Pediatric) | ABBVIE | Salts Of Piperazine Compounds As D3/D2 Antagonists |
Jun, 2029
(3 years from now) | |
|
USRE47350 (Pediatric) | ABBVIE | NA |
Jan, 2030
(3 years from now) | |
|
USRE49110 (Pediatric) | ABBVIE | NA |
Jan, 2030
(3 years from now) | |
|
USRE49302 (Pediatric) | ABBVIE | NA |
Jan, 2030
(3 years from now) | |
|
US7737142 (Pediatric) | ABBVIE | (Thio)Carbamoyl-Cyclohexane Derivatives As D3/D2 Receptor Antagonists |
Mar, 2030
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 17, 2020 |
| M(M-213) | Nov 09, 2020 |
| New Indication(I-798) | May 24, 2022 |
| New Indication(I-904) | Dec 16, 2025 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
NCE-1 date: 18 September, 2019
Market Authorisation Date: 18 December, 2025
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of VRAYLAR before its drug patent expiration?
More Information on Dosage
VRAYLAR family patents
32. Vykoura patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12564592 | AVYXA | NA |
Dec, 2044
(18 years from now) | |
Drugs and Companies using LEUCOVORIN CALCIUM ingredient
Market Authorisation Date: 03 February, 2026
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
VYKOURA family patents
33. Wegovy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12551536 | NOVO NORDISK | NA |
Oct, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Product(NP) | Dec 22, 2028 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
| New Indication(I-973) | Aug 15, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Method of weight reduction via subcutaneous administration
Dosage: SOLUTION
How can I launch a generic of WEGOVY before its drug patent expiration?
More Information on Dosage
WEGOVY family patents
34. Yuvezzi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455494 | VISUS | Preparations And Methods For Ameliorating Or Reducing Presbyopia |
May, 2030
(4 years from now) | |
| US12268662 | VISUS | Formulations Comprising Carbachol And Brimonidine To Enhance Anti- Presbyopia Effects |
Nov, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 28, 2029 |
Drugs and Companies using BRIMONIDINE TARTRATE; CARBACHOL ingredient
Market Authorisation Date: 28 January, 2026
Treatment: Treatment of presbyopia in adults by administration of brimonidine and carbachol once daily
Dosage: SOLUTION/DROPS
More Information on Dosage
YUVEZZI family patents
35. Zepbound patent expiration
ZEPBOUND IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12343382 | ELI LILLY | Methods Of Using A Gip/Glp1 Co-Agonist For Therapy |
Jul, 2039
(13 years from now) | |
| US12453758 | ELI LILLY | Method Of Using A Gip/Glp1 Co-Agonist For Diabetes |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
| M(M-82) | Oct 18, 2027 |
| New Indication(I-958) | Dec 20, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: Method of improving weight management by administering a once weekly escalation dose of 2.5 mg, 7.5 mg, or 12.5 mg of tirzepatide for at least 2 weeks and a once-weekly maintenance dose of 5 mg, 10 mg...
Dosage: SOLUTION
More Information on Dosage
ZEPBOUND family patents
36. Zepbound Kwikpen patent expiration
ZEPBOUND KWIKPEN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12343382 | ELI LILLY | Methods Of Using A Gip/Glp1 Co-Agonist For Therapy |
Jul, 2039
(13 years from now) | |
| US12453758 | ELI LILLY | Method Of Using A Gip/Glp1 Co-Agonist For Diabetes |
Jul, 2039
(13 years from now) | |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: Method of treating obesity by administering a once weekly escalation dose of 2.5 mg, 7.5 mg, or 12.5 mg of tirzepatide for at least 2 weeks and a once-weekly maintenance dose of 5 mg, 10 mg, or 15 mg ...
Dosage: SOLUTION
More Information on Dosage
ZEPBOUND KWIKPEN family patents
37. Zunveyl patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12551491 | ALPHA COGNITION | NA |
Jul, 2045
(19 years from now) | |
Drugs and Companies using BENZGALANTAMINE GLUCONATE ingredient
Market Authorisation Date: 26 July, 2024
Treatment: Treatment of mild to moderate dementia of the alzheimer's type
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
ZUNVEYL family patents